JP2025106475A5 - - Google Patents

Info

Publication number
JP2025106475A5
JP2025106475A5 JP2025064503A JP2025064503A JP2025106475A5 JP 2025106475 A5 JP2025106475 A5 JP 2025106475A5 JP 2025064503 A JP2025064503 A JP 2025064503A JP 2025064503 A JP2025064503 A JP 2025064503A JP 2025106475 A5 JP2025106475 A5 JP 2025106475A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
dose
compound
patient
cardiomyopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025064503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025106475A (ja
Filing date
Publication date
Priority claimed from JP2021568909A external-priority patent/JP2022535195A/ja
Application filed filed Critical
Publication of JP2025106475A publication Critical patent/JP2025106475A/ja
Publication of JP2025106475A5 publication Critical patent/JP2025106475A5/ja
Pending legal-status Critical Current

Links

JP2025064503A 2019-05-19 2025-04-09 収縮不全の処置 Pending JP2025106475A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962849936P 2019-05-19 2019-05-19
US62/849,936 2019-05-19
US201962852739P 2019-05-24 2019-05-24
US62/852,739 2019-05-24
JP2021568909A JP2022535195A (ja) 2019-05-19 2020-05-18 収縮不全の処置
PCT/US2020/033438 WO2020236736A1 (en) 2019-05-19 2020-05-18 Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021568909A Division JP2022535195A (ja) 2019-05-19 2020-05-18 収縮不全の処置

Publications (2)

Publication Number Publication Date
JP2025106475A JP2025106475A (ja) 2025-07-15
JP2025106475A5 true JP2025106475A5 (enExample) 2026-03-11

Family

ID=70978663

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568909A Withdrawn JP2022535195A (ja) 2019-05-19 2020-05-18 収縮不全の処置
JP2025064503A Pending JP2025106475A (ja) 2019-05-19 2025-04-09 収縮不全の処置

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021568909A Withdrawn JP2022535195A (ja) 2019-05-19 2020-05-18 収縮不全の処置

Country Status (16)

Country Link
US (2) US20220265629A1 (enExample)
EP (1) EP3972597A1 (enExample)
JP (2) JP2022535195A (enExample)
KR (1) KR20220009440A (enExample)
CN (1) CN114173782A (enExample)
AU (2) AU2020279710A1 (enExample)
BR (1) BR112021023074A2 (enExample)
CA (1) CA3138080A1 (enExample)
CL (1) CL2021003045A1 (enExample)
CO (1) CO2021015505A2 (enExample)
IL (1) IL288051A (enExample)
MX (2) MX2021014109A (enExample)
PE (1) PE20220426A1 (enExample)
SG (1) SG11202112723PA (enExample)
TW (2) TW202541801A (enExample)
WO (1) WO2020236736A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020315605A1 (en) 2019-07-16 2022-03-03 MyoKardia, Inc. Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide
KR102752382B1 (ko) * 2019-09-20 2025-01-09 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 안지오텐신 ii 수용체 길항제 대사물질 및 nep 억제제의 복합체의 심부전 치료에서의 용도
IL298885A (en) * 2020-06-15 2023-02-01 Myokardia Inc Treatment of atrial function
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure
US20250025460A1 (en) * 2021-12-02 2025-01-23 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
WO2005117882A2 (en) * 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
US8324178B2 (en) * 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
JP2014088342A (ja) * 2012-10-30 2014-05-15 Kowa Company Ltd ベンゾオキサジアゾール誘導体を有効成分とするｍｋ２阻害剤
PH12021553074A1 (en) * 2015-01-22 2023-03-06 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
LT3645002T (lt) * 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
WO2019006325A1 (en) * 2017-06-30 2019-01-03 Equalaire Systems, Inc. VENT CAP OF HUB CAP

Similar Documents

Publication Publication Date Title
JP2022535195A5 (enExample)
Porcari et al. Transthyretin amyloid cardiomyopathy: an uncharted territory awaiting discovery
Gartzonikas et al. Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy
LINDE‐EDELSTAM et al. Longevity in patients with high degree atrioventricular block paced in the atrial synchronous or the fixed rate ventricular inhibited mode
JP2023529502A5 (enExample)
US20230293548A1 (en) Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)
US20240091203A1 (en) Methods for treating non-obstructive hypertrophic cardiomyopathy
Greenberg Medical management of patients with heart failure and reduced ejection fraction
Zhang et al. Management of hypertrophic cardiomyopathy
Argirò et al. Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: real-world experience in a National Referral Center
WO2024097284A1 (en) Mavacamten and derivatives thereof for use in treating atrial dysfunction
Rossi et al. Effects of ivabradine on right ventricular systolic function in patients with chronic obstructive pulmonary disease and cor pulmonale
Ramadan et al. Omecamtiv mecarbil in systolic heart failure: clinical efficacy and future directions of a novel myosin-activating inotropic agent
Shono et al. Glucocorticoid-sensitive paroxysmal atrial fibrillation, sick sinus syndrome, and mitral regurgitation in a patient with malignant rheumatoid vasculitis
Abel et al. Prognostic value of mitral valve regurgitation in patients with heart failure with mildly reduced ejection fraction
Chen Heart failure with preserved ejection fraction in older adults
Talerico et al. A case of transient constrictive pericarditis after COVID-19
Steffen et al. Prognostic impact of left ventricular dilatation in heart failure with mildly reduced ejection fraction
Džubur et al. Cardiomyopathies
TH2101007135A (th) เภสัชภัณฑ์สำหรับการรักษาการทำหน้าที่ความผิดปรกติช่วงหัวใจบีบตัวและภาวะหัวใจ ล้มเหลวที่มีสัดส่วนการบีบตัวของหัวใจที่ลดลง
Galas et al. The differences between ambulatory and hospitalized heart failure patients who have mildly reduced or preserved ejection fractions: Lessons learned from the HF-POL study
Șuș et al. To pace or not to pace? Or how to pace?
Suzuki et al. Impact of Corticosteroid Use on the Clinical Response and Prognosis in Patients with Cardiac Sarcoidosis who Underwent an Upgrade to Cardiac Resynchronization Therapy
Hogwood et al. The effects of anakinra on cardiorespiratory fitness in heart failure stratified by age in phase II clinical trials
Thaman et al. Hypertrophic cardiomyopathy: management issues in the new millennium